The AMADEUS clinical trial sheds light on how biomarkers can predict how patients respond to immune checkpoint inhibitor treatments like nivolumab and ipilimumab.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
